2MD, Istanbul Health Sciences University, Basaksehir Cam and Sakura City Hospital, Ophthalmology Department, Istanbul, Türkiye DOI : 10.37845/ret.vit.2024.33.7 Purpose: To evaluate the effects of switching between vascular endothelial growth factor inhibitors (anti-VEGF) treatments in patients with extensive serous pigment epithelial detachment (sPED) due to neovascular age-related macular degeneration (nAMD).
Materials and Methods: This was a retrospective analysis of data where 38 patients (38 eyes) with fovea involving sPED of ?200 ?m measured manually using the caliper on the OCT due to AMD. The cases were divided into 2 groups. Group 1: included patients who were initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and then switched to intravitreal Aflibercept (2.0 mg/0.05ml). Group 2: included patients who were initially treated with intravitreal Aflibercept (2.0 mg/0.05ml) and then switched to intravitreal Ranibizumab (0.5 mg/0.05 ml). The outcome measures of best-corrected visual acuity (BCVA), PED height, PED width, the presence of subretinal fluid (SRF), intraretinal fluid (IRF), number of injections, and follow-up periods.
Results: At baseline, all patients in Group 1 had SRF. At switch, Group 1:22(%100) eyes, Group 2:16(%100) eyes had SRF. After the switch last visit, Group 1:11(%50) eyes, Group 2:8(%50) eyes had SRF (p=1.00). At baseline, Group 1:13(%59) eyes, Group 2:5(%31) eyes had IRF. At switch, Group 1: 1(%4.5) eyes, Group 2:1(%6) eyes had IRF. After switching the last visit, Group 1:1(%4.5) eyes, Group 2:1(%6) eyes had IRF (p= 0.816).
Conclusions: Our study found that both anti-VEGF switch treatments showed similar anatomical and functional effectiveness with a significant reduction in PED height and increases SRF, IRF absorption.
Keywords : Intraretinal fluid, Neovascular age-related macular degeneration, Pigment epithelial detachment, Subretinal fluid